Attention!

This page contains information about prescription medications. According to the Russian regulatory requirements, this information can be available only for medical or pharmaceutical stuff.

Do you confirm that you are a medical of pharmaceutical specialist?

Report an adverse reaction
Ru Eng
Main page — Our products —
Elizaria®
Elizaria®

Elizaria®

INN: eculizumab

Description
Indications for use
Articles for specialists

A humanized monoclonal antibody that binds to the human complement protein C5 and inhibits the activation of complement-mediated cytolysis.

Elizaria® inhibits the activation of the terminal complement complex in humans, restores the regulation of complement activity in the blood.

Elizaria® prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH), as well as excessive activation of the terminal complement complex in patients with atypical hemolytic uremic syndrome (aHUS).

Eculizumab treatment in patients leads to a significant decrease in hemolysis, frequency of thrombosis, dependence on blood transfusion in patients with paroxysmal nocturnal hemoglobinuria, and significantly improves renal function in patients with atypical hemolytic uremic syndrome.

GENERIUM is the only company in the world that has developed and manufactured a biosimilar of eculizumab.:

ЛП-№(000140)-(РГ-RU) от 18.02.2021

Instructions for medical use of the drug Elizaria

260.74 Kb

  1. A case report of atypical hemolytic-uremic syndrome treatment with the first Russian eculizumab in adult patient.

    Authors: Lavrishcheva IV, Jakovenko AA, Kudlay DA

    2020 yr.

    Read

  2. Phase III Clinical Trial of Elizaria® and Soliris® in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria: Results of Comparative Analysis of Eicacy, Safety, and Pharmacological Data.

    Authors: Aleksandr Kulagin Vadim Ptushkin, MD PhD Professor Elena Lukina, MD PhD Professor Elena Gapchenko, MD Oksana Markova, MD MSc Eugene Zuev, MD Dmitry Kudlay, MD PhD Professor

    2020 yr.

    Read

  3. Clinical and Economic Aspects of the First Biosimilar Eculizumab use in Patients with Rare Diseases.

    Authors: Ivan S. Krysanov, Vera S. Krysanova, Viktoriya Yu. Ermakova

    2022 yr.

    Read

  4. Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of eculizumab.

    Authors: Alexander D. Kulagin, Vadim V. Ptushkin, Elena A. Lukina, Igor L. Davydkin, Alexander V. Korobkin, Vladimir S. Shamrai, Tatyana S. Konstantinova, Tatyana S. Kaporskaya, Tatyana A. Mitina, Tatyana I. Ksenzova, Evgeny V. Zuev, Oksana A. Markova, Elena V. Gapchenko, Dmitry A. Kudlay

    2021 yr.

    Read
Read more:
Our website uses cookies. By continuing to use it, you consent to the processing of personal data in accordance with the privacy policy.